Literature DB >> 22793859

Economic impact of human papillomavirus-associated head and neck cancers in the United States.

Diarmuid Coughlan1, Kevin D Frick.   

Abstract

Cases of human papillomavirus (HPV)-associated head and neck cancers are rapidly increasing in the United States. Little is known about the economic burden of these cancers. A literature review identified 7 studies that characterized aspects of the overall economic burden of HPV-associated head and neck cancers in the United States. Other cost studies are detailed to highlight the clinical reality in treating these patients. As the clinical awareness of the role of HPV in head and neck cancers continues, the economic impact of cancers caused by this virus will have implications for the role of various preventive measures.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22793859     DOI: 10.1016/j.otc.2012.05.002

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  3 in total

1.  Long-term workforce participation patterns following head and neck cancer.

Authors:  Alison Pearce; Aileen Timmons; Eleanor O'Sullivan; Pamela Gallagher; Rachael Gooberman-Hill; Audrey Alforque Thomas; Michal Molcho; Phyllis Butow; Linda Sharp
Journal:  J Cancer Surviv       Date:  2014-07-25       Impact factor: 4.442

2.  Medical Care Cost of Oropharyngeal Cancer among Texas Patients.

Authors:  David R Lairson; Chi-Fang Wu; Wenyaw Chan; Kristina R Dahlstrom; Samantha Tam; Erich M Sturgis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-08-24       Impact factor: 4.254

3.  Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study.

Authors:  Chung-Jen Teng; Leh-Kiong Huon; Yu-Wen Hu; Chiu-Mei Yeh; Yee Chao; Muh-Hwa Yang; Tzeng-Ji Chen; Yi-Ping Hung; Chia-Jen Liu
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.